List of Lytgobi drug patents

Lytgobi is owned by Taiho Oncology.

Lytgobi contains Futibatinib.

Lytgobi has a total of 2 drug patents out of which 0 drug patents have expired.

Lytgobi was authorised for market use on 30 September, 2022.

Lytgobi is available in tablet;oral dosage forms.

Lytgobi can be used as method of treating intrahepatic cholangiocarcinoma.

Drug patent challenges can be filed against Lytgobi from 2026-09-30.

The generics of Lytgobi are possible to be released after 31 March, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9108973 TAIHO ONCOLOGY 3,5-disubstituted alkynylbenzene compound and salt thereof
Feb, 2033

(9 years from now)

US10434103 TAIHO ONCOLOGY Crystal of 3,5-disubstituted benzene alkynyl compound
Mar, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 30, 2027

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: 2026-09-30

Market Authorisation Date: 30 September, 2022

Treatment: Method of treating intrahepatic cholangiocarcinoma

Dosage: TABLET;ORAL

More Information on Dosage

LYTGOBI family patents

7

Japan

3

China

2

Portugal

2

Singapore

2

Russia

2

Spain

2

Brazil

2

Mexico

2

Korea, Republic of

2

Hong Kong

2

United States

2

Canada

2

Poland

2

Australia

2

Denmark

2

European Union

1

Malaysia

1

Philippines

1

Taiwan, Province of China

1

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in